In Vitro and In Vivo Evaluation of Injectable Strontium-Modified Calcium Phosphate Cement for Bone Defect Repair in
Hailiang Xu1,2, Lei Zhu1,2, Fang Tian1,2
1Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an 710054, China.
This study evaluated a new type of bone cement called strontium-modified calcium phosphate cement (SMPC) compared to traditional calcium phosphate cement (CPC). Researchers found that SMPC had better injectability, a shorter setting time, and improved mechanical strength. The addition of tristrontium silicate enhanced the cement's ability to promote new bone growth. In vitro and in vivo tests showed that SMPC outperformed CPC in promoting cell proliferation and bone regeneration. The study also confirmed that SMPC did not cause significant inflammation. The findings suggest that SMPC could be a promising material for bone repair applications.
Area of Science:
- Biomaterials in regenerative medicine
- Orthopedic surgery and bone repair
- Calcium phosphate cement applications
Background:
Current calcium phosphate cement (CPC) has limitations in osteoinductivity and mechanical strength. These constraints reduce its effectiveness in bone repair applications. While CPC remains a popular choice in bone grafting, its inability to stimulate new bone formation is a known limitation. Researchers have explored ways to enhance CPC properties through modifications. One promising approach involves incorporating strontium, which has shown potential in promoting bone growth and reducing resorption. However, the impact of strontium-modified CPC on bone regeneration is not fully understood. This gap motivated the development of a novel strontium-modified CPC (SMPC) to improve performance. The study aimed to evaluate the physicochemical and biological properties of SMPC compared to standard CPC.
Purpose Of The Study:
The goal of this study was to evaluate the performance of a novel strontium-modified calcium phosphate cement (SMPC) in bone repair. Researchers aimed to assess whether SMPC could overcome the limitations of traditional CPC by improving mechanical strength and osteoinductive properties. The study focused on comparing the physicochemical properties of SMPC and CPC, including injectability and setting time. In addition, the biological effects of SMPC on cell proliferation and differentiation were examined. The research also sought to determine the impact of SMPC on local inflammation and new bone formation in animal models. A rat model of vertebral defects was used to test the biomechanical performance of the cement. The study aimed to identify the optimal proportion of tristrontium silicate for enhancing CPC properties.
Main Methods:
Researchers developed a novel strontium-modified calcium phosphate cement (SMPC) by incorporating varying amounts of tristrontium silicate into standard CPC. The physicochemical properties of SMPC and CPC were evaluated using standard assays. Scanning electron microscopy was used to analyze the microstructure of the cements. In vitro experiments were conducted to assess the effect of SMPC on cell proliferation and differentiation. The local inflammatory response to SMPC implantation was also evaluated in vivo. A rat model of isolated vertebral defects was used to test the biomechanical properties of the cements. Compressive strength measurements were taken to compare the mechanical performance of SMPC and CPC. Histological staining was performed to assess new bone formation in the rat model. The study combined in vitro and in vivo approaches to evaluate the performance of SMPC.
Main Results:
The results showed that SMPC had better injectability and a shorter setting time compared to CPC. The addition of tristrontium silicate improved the mechanical strength of the cement. Specifically, the compressive strength of 5% SMPC reached 6.00 ± 0.74 MPa. However, this improvement decreased with higher tristrontium silicate concentrations. In vitro tests demonstrated that SMPC promoted cell proliferation and differentiation more effectively than CPC. Neither SMPC nor CPC induced significant inflammation in vivo. Histological analysis revealed that SMPC was more effective in promoting new bone regeneration compared to CPC. The osteogenic effect of SMPC was positively correlated with the amount of tristrontium silicate used.
Conclusions:
The findings suggest that 5% strontium-modified calcium phosphate cement (SMPC) is a promising material for bone repair. The study demonstrated that SMPC outperformed standard CPC in terms of injectability, setting time, and mechanical strength. The addition of tristrontium silicate enhanced the osteogenic properties of the cement. Histological evidence supported the role of SMPC in promoting new bone formation. The study also showed that SMPC did not induce significant inflammation in vivo. The optimal proportion of tristrontium silicate was found to be 5%, as higher amounts reduced the beneficial effects. These results indicate that SMPC could be a suitable substitute for traditional CPC in bone repair applications. The authors propose that further research is needed to confirm the long-term effects of SMPC in clinical settings.
Frequently Asked Questions
SMPC showed better injectability, shorter setting time, and improved mechanical strength compared to traditional CPC.
In vitro tests evaluated cell proliferation and differentiation, while in vivo studies assessed inflammation and new bone formation in a rat model.
The 5% concentration provided optimal mechanical and osteogenic properties, while higher concentrations reduced these benefits.
Histological staining confirmed that SMPC was more effective than CPC in promoting new bone regeneration.
Neither SMPC nor CPC induced significant inflammation in the in vivo rat model.
The authors suggest further studies to confirm the long-term effects of SMPC in clinical applications.
